Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review
- PMID: 31292800
- DOI: 10.1007/s10549-019-05352-3
Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review
Abstract
Purpose: Breast cancer is the most common cancer and leading cause of cancer death in women. Body composition parameters, especially those related to muscle, have become a growing focus of cancer research. In this review, we summarize the literature on breast cancer and muscle parameters as well as combine their outcomes for overall survival (OS), time to tumor progression (TTP), and chemotherapy toxicity in a meta-analysis.
Methods: A systematic search of the literature for randomized controlled trials and observational studies was conducted on MEDLINE, Cochrane CENTRAL, and EMBASE through May 1, 2019. Two reviewers independently searched and selected. Meta-analysis was conducted using a random-effects model. The risk of bias was evaluated using the Newcastle-Ottawa quality assessment for cohorts and GRADE summary of findings tool from Cochrane.
Results: A total of 754 articles were screened from which 6 articles and one abstract were selected. Using skeletal muscle index (SMI), patients classified as sarcopenic had a 68% greater mortality risk compared to non-sarcopenic patients (HR 1.68 95% CI 1.09-2.59, 5 studies) (p = .02) (i2 = 70%). Low muscle density was not predictive of OS (HR 1.44 95% CI 0.77-2.68, 2 studies) (p = .25) (i2 = 87%). Patients with sarcopenia (56%) had more grade 3-5 toxicity compared to non-sarcopenic (25%) (RR 2.17 95% CI 1.4-3.34, 3 studies) (p = .0005) (i2 = 0%). TTP was nearly 71 days longer in advanced/metastatic patients classified as non-sarcopenic compared to patients with sarcopenia (MD - 70.75 95% CI - 122.32 to - 19.18) (p = .007) (i2 = 0%).
Conclusion: Our synthesis of the literature shows that patients with sarcopenia have more severe chemotherapy toxicity as well as shorter OS and TTP, and that low muscle density is prognostic of OS for women with metastatic breast cancer. Our findings suggest that in clinical practice, body composition assessment is valuable as a prognostic parameter in breast cancer.
Keywords: Breast cancer; Muscle measures; Myosteatosis; Sarcopenia.
Similar articles
-
Myosteatosis and prognosis in cancer: Systematic review and meta-analysis.Crit Rev Oncol Hematol. 2020 Jan;145:102839. doi: 10.1016/j.critrevonc.2019.102839. Epub 2019 Dec 20. Crit Rev Oncol Hematol. 2020. PMID: 31877534
-
Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.JAMA Oncol. 2018 Jun 1;4(6):798-804. doi: 10.1001/jamaoncol.2018.0137. JAMA Oncol. 2018. PMID: 29621380 Free PMC article.
-
Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):199-206. doi: 10.1002/jcsm.12371. Epub 2019 Jan 21. J Cachexia Sarcopenia Muscle. 2019. PMID: 30666831 Free PMC article.
-
Sarcopenia reduces overall survival in unresectable oesophageal cancer: a systematic review and meta-analysis.J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2630-2636. doi: 10.1002/jcsm.13082. Epub 2022 Sep 24. J Cachexia Sarcopenia Muscle. 2022. PMID: 36151845 Free PMC article. Review.
-
Low L3 skeletal muscle index associated with the clinicopathological characteristics and prognosis of ovarian cancer: a meta-analysis.J Cachexia Sarcopenia Muscle. 2023 Apr;14(2):697-705. doi: 10.1002/jcsm.13175. Epub 2023 Jan 31. J Cachexia Sarcopenia Muscle. 2023. PMID: 36720459 Free PMC article. Review.
Cited by
-
Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis.Cancers (Basel). 2024 Jan 31;16(3):596. doi: 10.3390/cancers16030596. Cancers (Basel). 2024. PMID: 38339347 Free PMC article. Review.
-
Body composition and chemotherapy toxicities in breast cancer: a systematic review of the literature.J Cancer Surviv. 2024 Jan 11. doi: 10.1007/s11764-023-01512-z. Online ahead of print. J Cancer Surviv. 2024. PMID: 38206431 Review.
-
Association of body composition and surgical outcomes in patients with early-stage breast cancer.Breast Cancer Res Treat. 2023 Nov;202(2):305-311. doi: 10.1007/s10549-023-07060-5. Epub 2023 Aug 28. Breast Cancer Res Treat. 2023. PMID: 37639062
-
Hematologic toxicities, sarcopenia, and body composition change in breast cancer patients undergoing neoadjuvant chemotherapy.Support Care Cancer. 2023 Jun 24;31(7):419. doi: 10.1007/s00520-023-07890-5. Support Care Cancer. 2023. PMID: 37354335
-
Extracellular Vesicles and Their Zeta Potential as Future Markers Associated with Nutrition and Molecular Biomarkers in Breast Cancer.Int J Mol Sci. 2023 Apr 6;24(7):6810. doi: 10.3390/ijms24076810. Int J Mol Sci. 2023. PMID: 37047783 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
